{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:43:00Z","timestamp":1761986580942,"version":"build-2065373602"},"reference-count":48,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:p>Substantial progress in our understanding of chronic urticaria has been accomplished in recent years. We now recognize the heterogeneity of this condition, which is comprised of a number of endotypes and phenotypes. Laboratory testing to identify a cause for chronic urticaria has been\n discouraged, as this does not lead to improved outcomes and is not cost-effective; however, evidence has shown selected laboratory tests are important for their prognostic value. Therapeutic options for chronic urticaria, particularly for patients who are antihistamine-resistant, have also\n improved. Despite this, chronic urticaria has continued to be a vexatious condition for both patients and health care providers, and many patients continue to experience unmet needs. Guidelines recommend a step-care approach for management of chronic urticaria that can encourage substantial\n improvement in clinical course and quality of life. Use of anti-IgE therapy for more than the past decade has enabled many patients with antihistamine-resistant chronic urticaria to achieve improved outcomes; however, a substantial proportion continue to experience ongoing symptoms and impaired\n quality of life. The armamentarium for management of patients with refractory chronic urticaria has recently expanded, and will soon expand further. This article focuses on the approach to management of antihistamine-resistant patients who continue to experience poorly controlled chronic urticaria\n despite anti-IgE therapy prescribed at FDA-approved doses.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250072","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T04:32:17Z","timestamp":1761712337000},"page":"455-461","source":"Crossref","is-referenced-by-count":1,"title":["Management of chronic urticaria: Treatment options when omalizumab fails"],"prefix":"10.2500","volume":"46","author":[{"given":"David M.","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJMra2120166","article-title":"Chronic urticaria","volume":"387","author":"Lang","year":"2022","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.anai.2024.10.026","article-title":"Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine.","volume":"134","author":"Lang","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bjd.19561","article-title":"The global burden of chronic urticaria for the patient and society","volume":"184","author":"Goncalo","year":"2021","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/all.14547","article-title":"Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2024.05.020","article-title":"The future of targeted therapy in chronic spontaneous urticaria","volume":"133","author":"Min","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamadermatol.2018.3970","article-title":"\u03b1-Gal syndrome vs chronic urticaria","volume":"155","author":"Pollack","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.anai.2013.07.031","article-title":"Contemporary approaches to the diagnosis and management of physical urticaria","volume":"111","author":"Lang","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2012.01.043","article-title":"Chronic urticaria and autoimmunity: associations found in a large population study","volume":"129","author":"Confino-Cohen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archdermatol.2011.682","article-title":"Cancer risk in patients with chronic urticaria: a population-based cohort study","volume":"148","author":"Chen","year":"2012","journal-title":"Arch Dermatol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.anai.2011.06.008","article-title":"Utility of routine laboratory testing in management of chronic urticaria\/angioedema","volume":"107","author":"Tarbox","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jaip.2019.11.004","article-title":"Optimizing value in the evaluation of chronic spontaneous urticaria: a cost-effectiveness analysis","volume":"8","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","article-title":"Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"11","author":"Chuang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"crossref","first-page":"101068","DOI":"10.1016\/j.waojou.2025.101068","article-title":"Diagnostic testing for chronic spontaneous urticaria with or without angioedema: the do\u2019s, don\u2019t and maybe\u2019s","volume":"18","author":"Bernstein","year":"2025","journal-title":"World Allergy Organ J"},{"key":"B16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cea.12494","article-title":"BSACI guideline for the management of chronic urticaria and angioedema","volume":"45","author":"Powell","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"B18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1081-1206(10)60543-1","article-title":"Oral corticosteroid-dependent asthma: a 30-year review","volume":"99","author":"Randhawa","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B19","first-page":"181","article-title":"Remittive therapy in rheumatoid arthritis: clinical uses and mechanisms of action","volume":"14","author":"Lipsky","year":"1984","journal-title":"Agents Actions Suppl"},{"key":"B20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0950-3579(94)80030-8","article-title":"Treatment of psoriatic arthritis","volume":"8","author":"Cu\u00e9llar","year":"1994","journal-title":"Baillieres Clin Rheumatol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1081-1206(10)63332-7","article-title":"Steroid-resistant asthma: evaluation and management","volume":"77","author":"Nimmagadda","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1503\/cmaj.090089","article-title":"Asthma that is unresponsive to usual care","volume":"182","author":"Chapman","year":"2010","journal-title":"CMAJ"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archderm.142.10.1337","article-title":"Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine","volume":"142","author":"McGirt","year":"2006","journal-title":"Arch Dermatol"},{"key":"B24","first-page":"254","article-title":"Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study","volume":"85","author":"Cassano","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.7326\/0003-4819-110-10-848_1","article-title":"Methotrexate in corticosteroid-resistant urticaria.","volume":"110","author":"Weiner","year":"1989","journal-title":"Ann Intern Med."},{"key":"B26","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.jaip.2018.12.023","article-title":"Effectiveness and safety of oral tacrolimus in refractory chronic urticaria.","volume":"7","author":"Dorman","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1444-0903.2004.00532.x","article-title":"Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation","volume":"34","author":"Reeves","year":"2004","journal-title":"Intern Med J"},{"key":"B28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jaip.2014.06.004","article-title":"Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria","volume":"2","author":"Morgan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1346-8138.2001.tb00137.x","article-title":"Stanozolol in chronic urticaria: a double blind, placebo controlled trial","volume":"28","author":"Parsad","year":"2001","journal-title":"J Dermatol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","article-title":"Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Vena","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","article-title":"Randomized double-blind study of cyclosporin in chronic \u2018idiopathic\u2018 urticaria.","volume":"143","author":"Grattan","year":"2000","journal-title":"Br J Dermatol"},{"key":"B32","first-page":"285","article-title":"Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation","volume":"24","author":"Di Gioacchino","year":"2003","journal-title":"Allergy Asthma Proc"},{"key":"B33"},{"key":"B34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40629-022-00235-4","article-title":"Efficacy and safety of medications for antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis","volume":"32","author":"Kendziora","year":"2022","journal-title":"Allergo J Int"},{"key":"B38","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000529250","article-title":"Analysis of the efficacy and recurrence of omalizumab use in the treatment of chronic spontaneous urticaria and chronic inducible urticaria","volume":"184","author":"Yu","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"author":"Jeremias","key":"B39","article-title":"FDA approves first omalizumab biosimilar"},{"key":"B40","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/all.16446","article-title":"CT-P39 compared with reference omalizumab in chronic spontaneous urticaria: results from a double-blind, randomized, active-controlled, phase 3 study","volume":"80","author":"Saini","year":"2025","journal-title":"Allergy"},{"key":"B41"},{"key":"B42","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s13555-024-01231-y","article-title":"Dupilumab reduces urticaria activity, itch, and hives in patients with chronic spontaneous urticaria regardless of baseline serum immunoglobulin E levels","volume":"14","author":"Maurer","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/17512433.2022.2120469","article-title":"The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis","volume":"15","author":"Zhou","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","article-title":"Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria: the RILECSU phase 2 randomized clinical trial","volume":"161","author":"Gim\u00e9nez-Arnau","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000006\/art00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:22:42Z","timestamp":1761974562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,1]]}},"alternative-id":["1088-5412(20251101)46:6L.455;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250072","relation":{},"ISSN":["1088-5412"],"issn-type":[{"type":"print","value":"1088-5412"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}